In a nutshell The authors aimed to determine the safety and efficacy of saxagliptin (Onglyza) as an add-on treatment in patients with type 2 diabetes already receiving treatment with dapagliflozin (Farxiga) and metformin (Glucophage). The authors concluded that using saxagliptin as an add-on treatment for 52 weeks resulted in improvements in blood...
Read MoreIn a nutshell The authors aimed to determine the benefits of adding or switching to insulin therapy in type 2 diabetes patients not responding to treatment with glucagon-like peptide-1 receptor agonists (GLP- 1RA). The authors concluded that the earlier addition of insulin was associated with better glycemic control. The authors suggest that patients...
Read More
In a nutshell The authors aimed to determine the benefit of treatment with exenatide (Byetta) once weekly and dapagliflozin (Farxiga) once daily compared to exenatide or dapagliflozin alone in type 2 diabetes. The authors concluded that the combination treatment improved blood glucose control and reduced...
Read More
In a nutshell The authors aimed to determine the association between semaglutide (NN9535) and cardiovascular (CVD) outcomes in patients with type 2 diabetes. The authors concluded that in patients at high CVD risk, the rate of CVD death, heart attack and stroke was significantly lower in patients who received semaglutide compared to...
Read MoreIn a nutshell The main objective of this trial is to determine whether islet cell transplantation (ICT) using anti-thymocyte globulin (ATG) is a safe and effective treatment for type I diabetes. The main outcome to be measured is number of patients who no longer need insulin therapy following transplantation. This trial is being held in Duarte,...
Read More
In a nutshell This study compared the outcomes of bariatric surgery between patients with early onset (before age 40) and late onset (after age 40) type 2 diabetes. They found that bariatric surgery had more successful outcomes in those with early onset type 2 diabetes. Some background As the number of patients with type 2 diabetes (T2D) continues...
Read More
In a nutshell This study examined whether alogliptin is safe and effective as an add-on therapy to metformin in patients with type 2 diabetes who require more intense control of blood glucose levels. The authors concluded that patients with type 2 diabetes who fail metformin single treatment are more likely to achieve better control...
Read MoreIn a nutshell This study examined whether poor control of blood glucose levels is associated with increased intraocular pressure in patients with diabetes. The authors concluded that poor control of blood glucose levels may contribute to higher intraocular pressure. Some background Chronic high blood glucose levels can result in damage to small...
Read MoreIn a nutshell This study examined whether insulin degludec is safe and effective when combined with metformin and liraglutide. The authors concluded that insulin degludec is safe and effective as an add-on therapy. Some background Patients with type 2 diabetes (T2D) initially produce insulin (hormone which...
Read More
In a nutshell This study investigated the safety and effectiveness of canagliflozin (Invokana) as an add-on to insulin therapy in type 1 diabetes. The study concluded that canagliflozin caused a decrease in HbA1c, body weight and insulin dose in adults with type 1 diabetes. Some background The standard treatment option for type 1 diabetes is...
Read More
In a nutshell This study investigated the effectiveness and safety of a combination therapy of sitagliptin (Januvia) and metformin (Glucophage) for type 2 diabetes patients. Some background Type 2 diabetes (T2D) is characterized by elevated blood glucose (sugar) levels. The main aim of treatment is to reduce blood glucose levels. This...
Read More
In a nutshell This study aimed to determine the effectiveness and safety of empagliflozin (Jardiance) treatment in patients with type 2 diabetes. Some background Metformin (Glucophage) is typically the first treatment for type 2 diabetes when lifestyle changes fail to control blood gucose (sugar) levels. Commonly, metformin eventually...
Read More
